CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic w… Read more
CytomX Therapeutics Inc (CTMX) - Total Liabilities
Latest total liabilities as of September 2025: $50.87 Million USD
Based on the latest financial reports, CytomX Therapeutics Inc (CTMX) has total liabilities worth $50.87 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CytomX Therapeutics Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how CytomX Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CytomX Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of CytomX Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gujarat Gas Limited
NSE:GUJGASLTD
|
India | ₹46.72 Billion |
|
UroGen Pharma Ltd
NASDAQ:URGN
|
USA | $305.93 Million |
|
Uniqure NV
NASDAQ:QURE
|
USA | $659.64 Million |
|
Esquire Financial Holdings Inc
NASDAQ:ESQ
|
USA | $2.08 Billion |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
USA | $38.61 Million |
|
Shenzhen Feima International Supply Chain Co Ltd
SHE:002210
|
China | CN¥455.01 Million |
|
Zen Technologies Limited
NSE:ZENTEC
|
India | ₹2.08 Billion |
|
Premier Investments Ltd
AU:PMV
|
Australia | AU$432.10 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down CytomX Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CytomX Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CytomX Therapeutics Inc (2013–2024)
The table below shows the annual total liabilities of CytomX Therapeutics Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $120.99 Million | -51.46% |
| 2023-12-31 | $249.24 Million | -28.10% |
| 2022-12-31 | $346.64 Million | +38.64% |
| 2021-12-31 | $250.03 Million | -31.77% |
| 2020-12-31 | $366.44 Million | +26.28% |
| 2019-12-31 | $290.17 Million | -11.05% |
| 2018-12-31 | $326.23 Million | -0.46% |
| 2017-12-31 | $327.75 Million | +171.65% |
| 2016-12-31 | $120.65 Million | +69.58% |
| 2015-12-31 | $71.15 Million | -53.07% |
| 2014-12-31 | $151.60 Million | +159.32% |
| 2013-12-31 | $58.46 Million | -- |